In 2024, Genito Urinary System and Sex Hormones sales in the UK are forecasted at 13.53 USD per capita, marking a slight decline from the previous years. From 2024 to 2028, a gradual decrease in per capita sales is predicted, falling from 13.53 to 12.80 USD. The year-on-year decline is approximately 1.4% on average, translating to a compounded annual growth rate (CAGR) of about -1.4% over the next five years. This trend suggests a continuous reduction in market penetration or consumption per person.

Future trends to watch for include:

Potential shifts in healthcare policies affecting drug pricing and availability.
Emerging pharmaceutical innovations that might offset current declines.
Changing demographics and the prevalence of related health conditions.
Societal acceptance and demand for treatment within this category.